Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, with a growing healthcare burden due to an aging population and continued exposure to risk factors. To make matters worse, there are no drugs available that can modify the disease progression/burden of disease/rate of decline in lung function.
Now, a new potential avenue has emerged for combating COPD as Nordic Bioscience secured access to ECLIPSE, a highly relevant cohort of samples and clinical data—presenting an opportunity for potential pharmaceutical partners to leverage the right biomarker technologies.
COPD has traditionally been treated as a homogenous disease, despite significant differences in its underlying causes, making it difficult to develop effective and personalized treatment options. This “one-size-fits-all” approach has contributed to the lack of success in clinical trials and recruitment of the “right” patients remains a great obstacle.
Recent positive clinical trials enrolling a distinct subset of patients highlight the need to identify clinically actionable COPD endotypes to promote successful treatment options. To address these challenges, we aim to leverage large volumes of biomarker data, multi-omics data, and clinical characteristics to investigate possible pathobiological drivers in COPD.
Together with our future partner, we will focus on using data-driven approaches to identify treatable endotypes, which have the potential of improving the efficacy of clinical trial recruitment and aid in the discovery of targeted treatment targets. We believe that this project represents an essential step towards a more personalized and effective approach to treating COPD. By utilizing Nordic Bioscience’s inflammation- and extracellular matrix-based biomarkers, we have a unique tool to evaluate the (end products of) causal molecular pathways leading to lung tissue destruction.
Contact us today to explore partnership opportunities! With the correct approach, we can unravel the complexities of COPD and develop personalized treatments that may change patient outcomes. Together, we can make a difference.
The ECLIPSE cohort (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) stands as one of the most extensive studies that can provide a comprehensive description of COPD endotypes and define indicators that can foresee how the disease may advance over time.
By accessing the ECLIPSE samples and clinical data, and initiating a joint research project with Nordic Bioscience’s biomarkers, we have a unique opportunity to gain a more holistic understanding of the disease, encompassing various levels of biological information and interactions, and potentially, identifying novel targets for therapeutic intervention.
Previous data from an ECLIPSE subset has already demonstrated that Nordic Bioscience’s biomarkers are related to relevant COPD outcomes[1, 2]. A proof-of-concept data-driven cluster analysis revealed that our biomarkers identified prognostic endotypes with distinct patterns of progression that were not distinguishable by clinical characteristics[3]. This showcases how blood-based biomarkers reflecting relevant molecular pathways may be tools to identify clinically relevant endotypes.
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
